Microbial Influences: The Microbiome's Impact on Pancreatic Cancer Development and Progression

Area of Science:

• Oncology
• Microbiology
• Immunology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is challenging due to its dense stroma, limiting treatment efficacy.
• Despite advances in understanding PDAC genetics and pathways, patient survival remains low.
• The pancreatic tumor microbiome's role in PDAC initiation and progression is increasingly recognized but not fully understood.

Purpose of the Study:

• To review current evidence on the microbiome's influence on PDAC development and progression.
• To highlight the potential of microbiome modulation as a therapeutic strategy for PDAC.
• To emphasize the role of the microbiome in early PDAC detection, including premalignant conditions.

Main Methods:

• Literature review synthesizing current research on the pancreatic tumor microbiome and PDAC.
• Analysis of studies on microbial mechanisms influencing the tumor microenvironment (TME) and systemic immunity.
• Examination of evidence linking microbiome alterations to chronic inflammation and immune dysregulation in PDAC.

Main Results:

• The pancreatic tumor microbiome significantly influences PDAC initiation, progression, and the TME.
• Microbial dysbiosis can promote chronic inflammation, genetic mutations, and immune suppression, fostering PDAC.
• Microbiome modulation shows potential to enhance current therapies like chemotherapy and immunotherapy.

Conclusions:

• The pancreatic tumor microbiome is a critical factor in PDAC development and progression.
• Targeting the microbiome offers promising avenues for novel PDAC therapeutic strategies.
• Microbiome analysis may aid in the early detection of PDAC and related premalignant lesions.